Literature DB >> 8703725

Treatment of childhood steroid-resistant nephrotic syndrome with pulse methylprednisolone and cyclophosphamide.

G A Sa, J P Luis, E Mendonca, M Almeida, F C Rosa.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8703725     DOI: 10.1007/BF00862097

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  5 in total

1.  Controlled, multi-center trials are needed in pediatric nephrology.

Authors:  S A Mendoza; B M Tune
Journal:  Pediatr Nephrol       Date:  1992-11       Impact factor: 3.714

2.  Effect of methylprednisolone pulse therapy on cellular immunity abnormalities in a patient with lipoid nephrosis.

Authors:  K Matsumoto; M Ito; Y Abe
Journal:  Nephron       Date:  1990       Impact factor: 2.847

3.  Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents.

Authors:  S A Mendoza; V M Reznik; W R Griswold; A M Krensky; P D Yorgin; B M Tune
Journal:  Pediatr Nephrol       Date:  1990-07       Impact factor: 3.714

4.  Methylprednisolone treatment of patients with steroid-resistant nephrotic syndrome.

Authors:  F B Waldo; M R Benfield; E C Kohaut
Journal:  Pediatr Nephrol       Date:  1992-11       Impact factor: 3.714

5.  Treatment of childhood prednisone-resistant nephrotic syndrome and focal segmental glomerulosclerosis with intravenous methylprednisolone and oral alkylating agents.

Authors:  W R Griswold; B M Tune; V M Reznik; M Vazquez; D J Prime; P Brock; S A Mendoza
Journal:  Nephron       Date:  1987       Impact factor: 2.847

  5 in total
  2 in total

Review 1.  Pharmacotherapeutic review and update of idiopathic nephrotic syndrome in children.

Authors:  Silvia Manrique-Rodríguez; Cecilia M Fernandez-Llamazares; Maria Sanjurjo-Saez
Journal:  Pharm World Sci       Date:  2010-03-13

Review 2.  Focal segmental glomerulosclerosis.

Authors:  I Ichikawa; A Fogo
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.